Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNPH1 | O43598 | 8/20 | 0.73 |
| ▸ | P2RY1 | P47900 | 4/20 | 0.73 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.73 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.73 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.73 |
| ▸ | SRC | P12931 | 2/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.73 |
| ▸ | FBP1 | P09467 | 2/20 | 0.73 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.73 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.73 |
| ▸ | LDHA | P00338 | 1/20 | 0.73 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.73 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.73 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.73 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.73 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.73 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.73 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.73 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.73 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15249230 | 1.00 | DNPH1 (0.73) | DNPH1P2RY1P2RY2TAS1R3TAS1R1 | |
| SCHEMBL16406149 | 0.92 | P2RX3 (0.71) | DNPH1P2RY1P2RY2TAS1R3TAS1R1 | |
| SCHEMBL16406702 | 0.92 | P2RX3 (0.71) | DNPH1P2RY1P2RY2TAS1R3TAS1R1 | |
| SCHEMBL16406148 | 0.92 | P2RX3 (0.71) | DNPH1P2RY1P2RY2TAS1R3TAS1R1 | |
| SCHEMBL18269535 | 0.91 | P2RX3 (0.73) | P2RY1P2RY2SRCSMN1; SMN2TRPM2 | |
| SCHEMBL17737468 | 0.90 | NT5E (0.75) | P2RY11P2RX1P2RX3ALDH1A1 | |
| SCHEMBL10047768 | 0.90 | P2RY1 (0.63) | DNPH1P2RY1P2RY2TAS1R3TAS1R1 | |
| SCHEMBL16406701 | 0.88 | P2RY1 (0.66) | DNPH1P2RY1P2RY2TAS1R3TAS1R1 | |
| SCHEMBL16406151 | 0.88 | P2RY1 (0.66) | DNPH1P2RY1P2RY2TAS1R3TAS1R1 | |
| SCHEMBL15071485 | 0.88 | TAS1R3 (0.70) | DNPH1P2RY1P2RY2TAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180170990-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF NUCLEAR PROTEINS | MODERNATX, INC. | 2018-06-21 | — | — | US | disclosed |
| US-20180002393-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF ONCOLOGY-RELATED PROTEINS AND PEPTIDES | ARES CAPITAL CORPORATION, AS AGENT | 2018-01-04 | — | — | US | disclosed |
| US-9828416-B2 | Modified polynucleotides for the production of secreted proteins | MODERNATX, INC. (US) | 2017-11-28 | — | — | US | disclosed |
| US-20170028085-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF NUCLEAR PROTEINS | MODERNATX INC (US) | 2017-02-02 | — | — | US | disclosed |
| US-20160354492-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2016-12-08 | — | — | US | disclosed |
| US-9428535-B2 | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof | MODERNA THERAPEUTICS, INC. (US) | 2016-08-30 | — | — | US | disclosed |
| US-9221891-B2 | In vivo production of proteins | MODERNA THERAPEUTICS, INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-20150368665-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF SECRETED PROTEINS | ARES CAPITAL CORPORATION, AS AGENT | 2015-12-24 | — | — | US | disclosed |
| US-9095552-B2 | Modified polynucleotides encoding copper metabolism (MURR1) domain containing 1 | MODERNA THERAPEUTICS, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20150111248-A1 | IN VIVO PRODUCTION OF PROTEINS | MODERNA THERAPEUTICS, INC. (US) | 2015-04-23 | — | — | US | disclosed |
| US-20140343129-A1 | MODIFIED NUCLEIC ACIDS, AND ACUTE CARE USES THEREOF | MODERNATX, INC. | 2014-11-20 | — | — | US | disclosed |
| US-20140255467-A1 | MODIFIED POLYNUCLEOTIDES ENCODING CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN 4 | MODERNA THERAPEUTICS, INC. (US) | 2014-09-11 | — | — | US | disclosed |
| US-20140206755-A1 | MODIFIED POLYNUCLEOTIDES FOR TREATING ARYLSULFATASE A PROTEIN DEFICIENCY | MODERNA THERAPEUTICS, INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-20140105965-A1 | MODIFIED POLYNUCLEOTIDES ENCODING COPPER METABOLISM (MURR1) DOMAIN CONTAINING 1 | MODERNA THERAPEUTICS, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-20130245104-A1 | METHOD FOR PRODUCING A PROTEIN OF INTEREST IN A PRIMATE | modeRNA Therapeutics (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130115272-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | modeRNA Therapeutics (US) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160354492-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | DNPH1 1736/4885P2RY1 2661/4885P2RY2 2899/4885 |
| US-20180170990-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF NUCLEAR PROTEINS | POLN, POLRMT, MSH2 | DNPH1 2509/4885P2RY1 2813/4885P2RY2 3286/4885 |
| US-20140206755-A1 | MODIFIED POLYNUCLEOTIDES FOR TREATING ARYLSULFATASE A PROTEIN DEFICIENCY | POLRMT, MSH2, POLN | DNPH1 1764/4885P2RY1 1803/4885P2RY2 2147/4885 |
| US-20170028085-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF NUCLEAR PROTEINS | POLN, POLRMT, MSH2 | DNPH1 2509/4885P2RY1 2813/4885P2RY2 3286/4885 |
| US-20140255467-A1 | MODIFIED POLYNUCLEOTIDES ENCODING CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN 4 | PABPC4, TRDMT1, MSH2 | DNPH1 2450/4885P2RY1 3686/4885P2RY2 4011/4885 |
| US-20130245104-A1 | METHOD FOR PRODUCING A PROTEIN OF INTEREST IN A PRIMATE | IGF2BP1, PAIP1, PHAX | DNPH1 3115/4885P2RY1 4066/4885P2RY2 3872/4885 |
| US-20150111248-A1 | IN VIVO PRODUCTION OF PROTEINS | MSH2, POLRMT, POLN | DNPH1 2771/4885P2RY1 2987/4885P2RY2 3346/4885 |
| US-20180002393-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF ONCOLOGY-RELATED PROTEINS AND PEPTIDES | MSH2, POLN, MSH6 | DNPH1 3073/4885P2RY1 3094/4885P2RY2 3618/4885 |
| US-20150368665-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF SECRETED PROTEINS | MSH2, POLRMT, SARNP | DNPH1 3858/4885P2RY1 1880/4885P2RY2 2202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.